PolyPid (PYPD) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

PYPD Stock Forecast


PolyPid stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

PYPD Analyst Ratings


Buy

According to 3 Wall Street analysts, PolyPid's rating consensus is 'Buy'. The analyst rating breakdown for PYPD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 06, 2022Raymond James-OutperformDowngrade
Sep 02, 2022Guggenheim-NeutralUpgrade
Aug 11, 2022BMO CapitalOutperformOutperformHold
Row per page
Go to

PolyPid's last stock rating was published by Raymond James on Sep 06, 2022. The company Downgrade its PYPD rating from "null" to "Outperform".

PolyPid Financial Forecast


PolyPid Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

PolyPid's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYPD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

PolyPid EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict PYPD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PolyPid's previous annual EBITDA (undefined) of $NaN.

PolyPid Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-3.32M$-3.98M$-4.35M$-5.17M$-5.66M$-5.14M$-6.53M
High Forecast$-3.32M$-3.98M$-4.35M$-5.17M$-5.66M$-5.14M$-6.53M
Low Forecast$-3.32M$-3.98M$-4.35M$-5.17M$-5.66M$-5.14M$-6.53M
Surprise %-------

PolyPid's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYPD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

PolyPid SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

PolyPid's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PYPD last annual SG&A of $NaN (undefined).

PolyPid EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.66$-0.79$-0.87$-1.03$-1.13$-1.02$-1.30
High Forecast$-0.66$-0.79$-0.87$-1.03$-1.13$-1.02$-1.30
Low Forecast$-0.66$-0.79$-0.87$-1.03$-1.13$-1.02$-1.30
Surprise %-------

According to undefined Wall Street analysts, PolyPid's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYPD previous annual EPS of $NaN (undefined).

PolyPid Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INABIN8bio$0.30$14.004566.67%Buy
KPRXKiora Pharmaceuticals$3.68$120.003160.87%Buy
BWVOnconetix$0.18$4.002122.22%Buy
ELEVElevation Oncology$0.52$9.001630.77%Buy
PYPDPolyPid$3.33$25.00650.75%Buy
VACCBarinthus Biotherapeutics$5.00$22.00340.00%-
VRPXVirpax Pharmaceuticals$0.71$3.00322.54%-
INMBINmune Bio$6.25$22.00252.00%Buy
CUECue Biopharma$1.49$5.00235.57%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
PYXSPyxis Oncology$3.80$9.00136.84%Buy
ANIXAnixa Biosciences$3.45$7.50117.39%Buy
ZURAZura Bio$4.37$5.0014.42%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy

PYPD Forecast FAQ


Yes, according to 3 Wall Street analysts, PolyPid (PYPD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of PYPD's total ratings.

PolyPid's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-17.339M (high $-17.339M, low $-17.339M), average SG&A $0 (high $0, low $0), and average EPS is $-3.451 (high $-3.451, low $-3.451). PYPD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-16.828M (high $-16.828M, low $-16.828M), average SG&A $0 (high $0, low $0), and average EPS is $-3.349 (high $-3.349, low $-3.349).